Shigella sonnei causes shigellosis, a severe gastrointestinal illness that is sexually transmissible among men who have sex with men (MSM). Multidrug resistance in S. sonnei is common including against World Health Organisation recommended treatment options, azithromycin, and ciprofloxacin. Recently, an MSM-associated outbreak of extended-spectrum β-lactamase producing, extensively drug resistant S. sonnei was reported in the United Kingdom. Here, we aimed to identify the genetic basis, evolutionary history, and international dissemination of the outbreak strain. Our genomic epidemiological analyses of 3,304 isolates from the United Kingdom, Australia, Belgium, France, and the United States of America revealed an internationally connected outbreak with a most recent common ancestor in 2018 carrying a low-fitness cost resistance plasmid, previously observed in travel associated sublineages of S. flexneri. Our results highlight the persistent threat of horizontally transmitted antimicrobial resistance and the value of continuing to work towards early and open international sharing of genomic surveillance data.
Shigellosis is an enteric infection that transmits through the faecal-oral route, which can occur during sex between men who have sex with men (MSM). Between 2009 and 2014, an epidemic of sexually transmissible Shigella flexneri 3a occurred in England that subsequently declined. However, from 2019 to 2021, despite SARS-CoV-2 restrictions, S. flexneri 3a continued to re-emerge. We explored possible drivers of re-emergence by comparing host demography and pathogen genomics. Cases were primarily among 35–64 year old men in London. Genomic analyses of 502 bacterial isolates showed that the majority (58%) of re-emerging MSM strains were a clonal replacement of the original, with reduced antimicrobial resistance, conservation of plasmid col156_1, and two SNPs with 19 predicted effects. The absence of major changes in the pathogen or host demographics suggest that other factors may have driven the re-emergence of S. flexneri 3a and highlight the need for further work in the area.
Sexually transmissible gastrointestinal (enteric) infections cause oropharyngitis, hepatitis, enteritis, proctocolitis and anorectal disease, and can mimic neoplastic and inflammatory gastrointestinal disease. Sexually transmissible enteric infections are generally seen in men who have sex with men (MSM) due to sexual behaviours which risk faecal-oral transmission. Oropharyngeal and anorectal sexually transmitted infections (STIs) are transmitted via direct inoculation from oral and anal sexual behaviours. Shigella spp, Campylobacter spp, Salmonella spp, diarrhoeagenic Escherichia coli , Giardia duodenalis and Entamoeba histolytica are recognised sexually transmissible enteric faeco-oral pathogens in MSM. Neisseria gonorrhoeae , Chlamydia trachomatis, herpes simplex virus (HSV), Treponema pallidum subspecies pallidum (Syphilis), mpox and HSV cause sexually transmissible oropharyngeal and anorectal disease. Cryptosporidium, intestinal spirochaetosis , Blastocystis, Strongyloides stercoralis, Enterobius vermicularis and enteric viruses have infrequently been reported as sexually transmissible in MSM. Sexually transmissible enteric infections have increased in MSM over the past 35 years. Gastroenterologists and hepatologists do not generally enquire about sexual behaviours, but identifying sexually transmissible enteric infections is important due to high rates of bacterial antimicrobial resistance, and the additional management includes: bacterial antimicrobial susceptibility testing, testing for STIs/HIV, providing recommendations for sexual abstinence and partner notification; and onward referral to specialist sexual health clinics for sexual health prevention interventions. In this review, we highlight the STIs which can affect the gastrointestinal tract and provide some key management points for gastroenterologists and hepatologists.
In general, shigellosis is a self-limiting condition, and Shigella spp can be asymptomatic in MSM.4 The role of antimicrobial therapy in shigellosis is unclear: there are six international guidelines which provide varied recommendations on the antimicrobial treatment.5 Antimicrobial treatment is generally not recommended in asymptomatic people but should be considered in people with severe and prolonged symptoms, particularly those with comorbidities.5 The British Association of Sexual Health and HIV guidelines suggest that antimicrobials are reserved for hospitalised patients with sepsis or a prolonged illness, taking into consideration people who have significant comorbidities (eg, living with HIV or inflammatory bowel disease), and recommend seeking advice from expert microbiologists on the agent of choice, ideally driven by antimicrobial susceptibility testing.1 The currently available guidelines do not, however, provide any …
Antimicrobial resistance (AMR) is a major threat to human and animal health, in addition to environmental resilience. Countries set the agenda on their national action against AMR in the form of National Action Plans (NAPs), with the UK's latest NAP released in May, 2024. Advances in genomics have strengthened our ability to work towards NAP priorities; however, to date, no mapping of the role genomics plays in contributing to specific goals within the NAP has been undertaken. The UK Research and Innovation-funded Transdisciplinary Antimicrobial Resistance Genomics Network brought together a range of stakeholders to discuss the role of genomics for action on AMR and to deliver policy priority-led research, as outlined in the UK NAP 2024-29. We report our discussions in this Personal View, with key roles for genomics, including informing targeted stewardship in health-care settings, supporting AMR literacy, and supporting effective antimicrobial innovation. However, changes in infrastructure, communication, and cross-sector coordination are needed to support implementation.